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Abstract
Background:  There is a high and rising prevalence of cardiovascular risk in sub-Saharan Africa, a
development typical for countries in epidemiological transition. Contrary to recommendations in
treatment guidelines, medical interventions to prevent cardiovascular disease are implemented only on a
limited scale in these settings. There is a widespread concern that such treatment is not cost-effective
compared to alternative health interventions. The main objectives of this article are therefore to calculate
costs-, effects and cost-effectiveness of fourteen medical interventions of primary prevention of
cardiovascular disease in Tanzania, including Acetylsalicylic acid, a diuretic drug (Hydrochlorothiazide), a
β-blocker (Atenolol), a calcium channel blocker (Nifedepine), a statin (Lovastatin) and various
combinations of these.
Methods: Effect sizes were derived from systematic reviews or meta-analyses, and calculated as Disability
Adjusted Life Years (DALYs). Data on drug costs were calibrated to a Tanzanian setting. Other recurrent
and capital costs were derived from previous studies and reviewed by local experts. Expected lifetime
costs and health outcomes were calculated using a life-cycle model. Probabilistic cost-effectiveness analysis
was performed using Monte Carlo simulation, and results presented as cost-effectiveness acceptability
curves and frontiers. The potential impacts of uncertainty in value laden single parameters were explored
in one-way sensitivity analyses.
Results: The incremental cost-effectiveness ratios for the fourteen interventions and four different levels
of risk (totally 56 alternative interventions) ranged from about USD 85 per DALY to about USD 4589 per
DALY saved. Hydrochlorothiazide as monotherapy is the drug yielding the most favorable cost-
effectiveness ratio, although not significantly lower than when it is combined in duo-therapy with Aspirin
or a β-blocker, in triple-therapy with Aspirin and a β-blocker, or than Aspirin given as mono-therapy.
Conclusion:  Preventive cardiology is not cost-effective for any patient group in this setting until
willingness to pay exceeds USD 85 per DALY. At this level of willingness to pay, the optimal intervention
is Hydrochlorothiazide to patients with very high cardiovascular risk. As willingness to pay for health
increase further, it becomes optimal to provide this treatment also to patients with lower cardiovascular
risk, and to substitute to more sophisticated interventions.
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Background
The epidemiological transition
Cardiovascular diseases (CVD) currently contributes to
almost one third of global mortality [1], and has been
projected to become the leading cause of global burden of
disease by 2020 [2]. In 2001 ischaemeic heart disease rep-
resented more than 12% and cerebrovascular diseases
almost 10% of the premature deaths globally [3]. The
increasing impact from CVD also takes place in develop-
ing countries, the so called epidemiological transition [1].
Studies from sub-Saharan Africa (SSA) and Tanzania show
that there is a high and rising prevalence of cardiovascular
risk in the population [1,4,5]. A survey of the population
of Dar es Salaam found an age-adjusted prevalence of
about 30% for blood pressure values larger or equal to
140/90 mmHg [5], which leads to increased risk of stroke
and coronary heart disease (CHD). The age-adjusted inci-
dence of cardiovascular diseases, like stroke, is further-
more several times higher in Tanzania than in Western
Europe [6], probably due to untreated hypertension [5,7].
Cardiologists have discussed whether medical interven-
tions to prevent cardiovascular disease in low-income
countries should be given priority, as compared to other
interventions competing for funding [8]. Medical inter-
ventions are recommended in international as well as
national treatment guidelines [9-11], but they are imple-
mented only on a very limited scale in sub-Saharan Afri-
can countries [11]. While some have argued that
pharmaceutical interventions to prevent cardiovascular
disease should not be provided due to high costs, others
have emphasized that this conclusion is based on an
information vacuum [8]. Given the resource situations in
many countries in SSA, we share the opinion that particu-
lar consideration should be given to the questions of
affordability and cost-effectiveness [11], and that more
economic evidence as such is useful.
To the best of our knowledge only one study has explored
the cost-effectiveness of preventive cardiology in Africa.
Murray and colleagues calculated that several medical
interventions to lower blood pressure and cholesterol are
cost-effective in two African regions [12]. They found that
for the region including East-Africa the cost effectiveness
of an absolute risk approach varied between 230 and
1010 international dollars per DALY averted depending
on the risk level [12]. These figures are taken from webta-
ble 2, and have been multiplied by 10 to adjust for a typ-
ing error in the publications (Lancet Department of
Error).
When considering health care priorities in Tanzania, the
study by Murray and colleagues is useful, but appear
insufficient as evidence base for two main reasons. First,
the cost-effectiveness ratios are based on aggregated data
for a region with large demographic, epidemiological and
socio-economic variation. Country specific studies are
therefore important, a point also emphasized by the
WHO CHOICE team [13]. Second, their study includes
only a sub-set of possible medical interventions. A large
range of available drug groups and combinations are
available and should be considered for implementation.
We have explored the relevance of 14 prevention alterna-
tives for Tanzania, which is a typical resource poor sub-
Saharan African setting. Similar to the Murray study, we
explore the relevance of these pharmaceutical interven-
tions within four different levels of absolute cardiovascu-
lar risk, so that the total amount of interventions under
consideration is 56.
There are large evidence gaps for preventive cardiology in
sub-Saharan Africa [11]. For example, no long-term pla-
cebo controlled trials for relevant drugs have been under-
taken in Africa. Facing this situation, one option would be
to delay our assessment until such evidence is available,
but in the light of the dramatic epidemiological develop-
ment taking place, we think this is too long for African
decision makers to wait for economical evidence. The
objectives of this paper are therefore to calculate costs-,
effects and cost-effectiveness for medical interventions to
prevent cardiovascular disease in a low-income country in
sub-Saharan Africa using the best available evidence. Our
analysis is limited to primary prevention to patients with
no history of previous cardiovascular events who are not
suffering from other major conditions like HIV-AIDS.
Description of interventions
We compared 14 alternative medical interventions for
preventive cardiology, including the alternative of no
treatment. The choice of interventions was based on inter-
national treatment recommendations [14], recommenda-
tions from a WHO expert meeting [15], Tanzanian
guidelines and consultations with local experts. All drugs
that are included are off-patent and can be purchased
from several producers at relatively low cost. The treat-
ment alternatives are based on five different drugs pro-
vided as mono-therapies, duo-therapies, triple-therapies
and a therapy combining four different drugs groups. We
also included a hypothetical "polypill" in the analysis
which remains to be manufactured, but has been
described as having "enormous potential in developing
countries" [16]. The "polypill" contains a statin, three
classes of antihypertensives at half standard dose, folic
acid and a low dose of aspirin [17]. An overview of the
alternative drugs and drug combinations and the average
dosages used in the analysis is given in Table 1.
ACE-inhibitors and other more recent drug classes are not
included in the analysis because they are too expensive for
widespread use in Africa and would most likely be domi-Cost Effectiveness and Resource Allocation 2007, 5:3 http://www.resource-allocation.com/content/5/1/3
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nated within our analytical framework. Whether or not
these recent drugs are good choices for patients with mul-
tiple contraindications or more complex risk patterns (e.g.
diabetes) would have to be assessed in a separate analysis.
We assume that cardiovascular risk can be assessed at reg-
ular health check-ups by considering risk factors that are
easily observable (age, blood pressure, sex, etc.) [14]. It is
assumed that two annual outpatient visits for monitoring
treatment and risk factors are necessary for low and
medium risk patients. For patients with high and very
high risk it is assumed that four visits are necessary the
first year and two annual visits thereafter. Finally, we
assume that such preventive cardiology can be performed
within the existing health service delivery system, but that
some resources are necessary for public awareness cam-
paigns and training of medical personnel.
Methods
Markov process model
We use a Markov process model to calculate clinical out-
comes and costs during the life cycles of people under the
alternative treatment scenarios. We assume that people
are eligible for preventive cardiology at the age of 45, and
that thereafter they receive treatment for their remaining
life spans. There are two exceptions to the latter assump-
tion. First, since our analysis is restricted to primary pre-
vention, only the first event is registered, and people who
experience a non-fatal stroke or coronary heart disease
(CHD) are transferred to secondary prevention. Second,
we assume that the provision of statins is stopped at the
age of 80, since the effect of such treatment is not well
documented for older people [18].
In the model (Figure 1), all people start out as non-symp-
tomatic. For each year that passes (Markov stage) people
may remain well, they may experience stroke or CHD, or
Table 1: The interventions, generic drug names and dosages for the drug combinations considered in the analysis.
Intervention Generic drug Daily dose
Aspirin (Asa) Acetylsalicylic acid 75 mg
Diuretic drug (Diu) Hydrochlorothiazide 25 mg
β-blocker (Bet) Atenolol 50 mg
Calcium antagonist (Cab) Nifedepine 40 mg
Statin (Sta) Lovastatin 40 mg
Aspirin + Diuretic drug (AsaDiu) Acetylsalicylic acid 75 mg
Hydrochlorothiazide 25 mg
Aspirin + β-blocker (AsaBet) Acetylsalicylic acid 75 mg
Atenolol 50 mg
Diuretic drug + β-blocker (DiuBet) Hydrochlorothiazide 25 mg
Atenolol 50 mg
Aspirin + Diuretic drug + β-blocker 
(AsaDiuBet)
Acetylsalicylic acid 75 mg
Hydrochlorothiazide 25 mg
Atenolol 50 mg
Aspirin + Diuretic drug + Statin (AsaDiuSta) Acetylsalicylic acid 75 mg
Hydrochlorothiazide 25 mg
Lovastatin 40 mg
Diuretic drug + β-blocker + Statin (DiuBetSta) Hydrochlorothiazide 25 mg
Atenolol 50 mg
Lovastatin 40 mg
Aspirin + β-blocker + Statin (AsaBetSta) Acetylsalicylic acid 75 mg
Atenolol 50 mg
Lovastatin 40 mg
Aspirin + Diuretic drug + β-blocker + Statin 
(AsaDiuBetSta)
Acetylsalicylic acid 75 mg
Hydrochlorothiazide 25 mg
Atenolol 50 mg
Lovastatin 40 mg
Hypothetical polypill Acetylsalicylic acid 75 mg
Hydrochlorothiazide 12.5 mg
Atenolol 25 mg
Nifedepine 20 mg
Lovastatin 20 mg
Folic acid 1 mgCost Effectiveness and Resource Allocation 2007, 5:3 http://www.resource-allocation.com/content/5/1/3
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they may die from other causes not related to preventive
cardiology. The probabilities for each of these outcomes
depend on the individual risk profiles, people's age and
the drugs being offered (see details below). The assumed
case fatality rates for Stroke and CHD are 27% and 51%,
respectively [19]. As mentioned earlier, people who expe-
rience non-fatal CV attacks are transferred to secondary
prevention. In other words we assume that they are
removed from preventive therapy, but the remaining life
expectancies are nevertheless calculated (without the ben-
eficial effects of preventive cardiology).
We used disability adjusted life years (DALYs) as the
measure of clinical outcome. DALYs were calculated using
standard assumptions [4], and a Tanzanian life table with
a life expectancy at birth of 46.5 years [20] was used to
assess the all cause risk of death at different ages (Table 2).
For the non-fatal cases, disability weights of 0.49 and
0.268 are applied for CHD and stroke, respectively [4]. All
monetary values are presented in 2005 US dollars (USD)
and costs and consequences are discounted at 3% at base-
line.
Calculating absolute risk
We calculated cost-effectiveness for four different risk lev-
els of cardiovascular events; low, medium, high and very
high; using an absolute risk approach. This implies that
the risk of cardiovascular disease for an individual is
assessed by taking into account all her or his known deter-
minants of risk rather than thresholds for single risk fac-
tors [12,21]. Absolute cardiovascular risk can be assessed
relatively easily in a clinical setting using standard meth-
odology, although there exist no risk-instrument vali-
dated for use in our context [10].
For the purpose of this study, we constructed four index
patients labeled "very high", "high", "medium" and "low"
using algorithms from the Framingham study [22,23].
The index patients were stratified by varying, blood pres-
sure (SBP), sex and smoking status, such that the annual
total CV risk for a person aged 50 with a very high risk pro-
file is higher than 3%. The definitions of people with
high, medium and low CV risk were set at 2–3%, 1.5–2%
and < 1.5%, respectively. The Framingham equations
were also used to calculate the impact of age on the risk of
stroke and CHD, as reported in Table 2.
In the risk calculations we used Tanzanian data on diabe-
tes prevalence [24], but assumed that patients otherwise
are asymptomatic, have no history of cardiovascular
events, and that they are not on hypertension treatment
when entered into the model. The remaining variables in
the Framingham equations are kept constant at mean
observed values from Framingham [22,23].
The above method only describes index-patients as exam-
ples of people with different risk levels. In our main anal-
ysis we calculate the effect of interventions for given
absolute levels of risk. The above assumptions are there-
fore not critical to the main analysis as long as the findings
and conclusions of the analysis are interpreted accord-
ingly, In the clinical setting, however, CV risk must be
assessed for individual patients and the choice of risk
instruments then becomes crucial.
Calculating treatment effects
Treatment effects for low dose diuretics and β-blockers,
acetylsalicylic acid and statins used as monotherapy were
taken from recent systematic reviews and meta-analyses
from Europe and USA [17,25]. Unfortunately, we found
no large long term clinical trials from Africa of drugs to
prevent CVD. Nor did we find any meta-analyses report-
ing the effect of calcium antagonist compared to placebo,
so we used a study reporting the relative risk compared to
diuretics and β-blockers [26].
For drug combinations we assumed multiplicative effects
[12,17]. This implies that the relative risk of the second
drug in e.g. a duo-therapy applies to the remaining risk
after the risk reduction of the first drug has been calcu-
lated. The assumption of multiplicative effects does not
seem to be controversial, as the drugs influence different
physiological mechanisms. It is potentially more prob-
lematic that studies on treatment effects generally have
been performed in Caucasian populations, and the trans-
ferability to black African populations is uncertain. The
applied treatment effects for the different drugs are
reported in Table 3.
Calculating cost
We calculated drug costs based on dosages from standard
treatment guidelines and information from the Interna-
tional Drug Price Indicator Guide [27]. We used the
median prices of the available buyer prices, representing
so called c.i.f. (cost free on board + insurance + freight). In
order to approximate the c.i.f.-s to local opportunity costs,
they were adjusted with a so called domestic margin of
1.43. This adjustment has been described elsewhere [13].
The prices of combination therapies were calculated by
adding the costs of the individual ingredients. The applied
prices of the different drugs are given in Table 4.
Facility costs are based on a comprehensive costing study
of Tanzanian health facilities [28]. To calculate the most
likely cost per health check up, we used the mean cost of
outpatient visits at four different health centers in Tanza-
nia. The recurrent facility costs of 0.90 USD per outpatient
visit include staff, medical supplies, utilities, stationary,
uniforms and linen, cleaning, maintenance and travel
[28]. Minimum and maximum values for uncertaintyCost Effectiveness and Resource Allocation 2007, 5:3 http://www.resource-allocation.com/content/5/1/3
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analysis were set at 0.70 and 1.22 USD per outpatient
visit. Capital facility costs of 0.32 USD per visit include
annualized costs of buildings, equipment, furniture and
transportation [28]. Minimum and maximum capital
costs are set at 0.13 and 0.57 USD per visit. We standard-
ize the discount rate used in the costing study from 10%
to 3%.
Well trained physicians can relatively easily assess cardio-
vascular risk of their patients at regular health check-ups
or when they see patients for other reasons. However,
although such passive case detection is certainly possible,
we acknowledge that widespread implementation of a
program of preventive cardiology warrants resources for
awareness campaigns, training of physicians and adminis-
The life cycle model used to calculate the costs-, effects and cost-effectiveness of the alternative interventions Figure 1
The life cycle model used to calculate the costs-, effects and cost-effectiveness of the alternative interventions.
Non- 
symptomatic 
Stroke 
event 
 CHD 
event 
Non-fatal 
stroke 
Non-fatal 
CHD
Dead 
Table 2: Example of index patients, with annual risks of stroke or CHD events, and all cause risk of death.
Index 
patient
Very high High Medium Low Very high High Medium Low
Sex Male Male Male Female Male Male Male Female
SBP 170 160 150 150 170 160 150 150
Smoking Yes No No No Yes No No No
Age Annual risk of stroke Annual risk of CHD All cause 
mortality
42 0.006 0.003 0.003 0.001 0.015 0.008 0.007 0.004 0.019
47 0.007 0.004 0.003 0.001 0.019 0.011 0.010 0.007 0.020
52 0.009 0.005 0.004 0.002 0.023 0.014 0.013 0.009 0.021
57 0.011 0.006 0.005 0.003 0.027 0.017 0.016 0.011 0.024
62 0.014 0.008 0.007 0.004 0.031 0.021 0.019 0.012 0.032
67 0.018 0.010 0.009 0.005 0.035 0.024 0.022 0.013 0.043
72 0.023 0.012 0.011 0.007 0.038 0.027 0.025 0.013 0.062Cost Effectiveness and Resource Allocation 2007, 5:3 http://www.resource-allocation.com/content/5/1/3
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tration above the facility level. We therefore apply a fixed
ratio of 20% of facility costs to cater for program costs of
scaling up preventive cardiology.
We did not include indirect patient costs (e.g. productivity
changes) or saved treatment costs from averted cases of
stroke and CHD. Although treatment costs in many set-
tings are likely to be substantial, it remains to be estab-
lished that good quality treatment and rehabilitation of
CV patients is currently a widespread practice in the Tan-
zanian health care system.
Net health benefits
We apply a net health benefit (NB) approach that disen-
tangles the cost-effectiveness assessment from potential
problems with ratio statistics as well as with interpretation
of the findings [29,30] by using the formula below
[31,32]:
NBi = ΔDALYi - (ΔCosti/λ)
The above formula is based on a simple rearrangement of
the decision rule that interventions are considered cost-
effective if the incremental cost-effectiveness ratio is
smaller than some cost-effectiveness threshold or value of
ceiling ratio (λ), and by defining the net benefits as the
balance on the right side of the intermediate expression
[30]:
The net-benefit formula compares the DALYs averted by
an intervention under consideration (DALYi) with the
minimum DALYs averted that would be necessary to con-
sider an intervention cost-effective given a certain cost
(Costi). At the same time we get a linear expression rather
than a ratio, thus avoiding several potentially problematic
features of ratio statistics [29]. An intervention (i) is con-
sidered cost-effective if it produces a positive net benefit,
in other words, if it averts more DALYs than the minimum
implied by the threshold. A negative net benefit, on the
other hand, means that the intervention is considered to
be not cost-effective.
Handling of uncertainty
We use distributions to capture the varying degree of
inherent uncertainty in the variables. This probabilistic
approach assesses simultaneous uncertainty in many var-
iables and is well suited to express overall model uncer-
tainty.
Monte Carlo simulations [33] were done with 5000 itera-
tions. For each iteration a value is randomly drawn from
each distribution and net health benefits calculated [32].
We assume that all relative risks are normally distributed,
and calculate standard deviations (SD) based on confi-
dence limits from the underlying meta-analyses
[17,25,26]. For drug costs [27] we apply triangular distri-
butions with minimum and maximum values at 20%
below and above most likely values, respectively. A trian-
gular distribution was chosen also for capital and recur-
rent facility costs, and maximum and minimum values
were set as the lowest and highest values from the health
centers in the costing study [28].
Δ
Δ
Δ
Δ
Δ
Δ Cost
DALY
DALY
Cost
NB DALY
Cost i
i
i
i
i
i <⇔< − ⇒ = − λ
λλ
   0
Table 4: Societal prices including markups of the alternative drugs. Minimum and Maximum values are calculated as most likely value 
-/+ 20%, respectively.
Intervention Strength/tablet Price/tablet (USD) Source: [27] Drug cost per year (USD) Min Max
Acetylsalicylic acid (Asa) 75 mg 0.0118 6.16 4.93 7.39
Hydrochlorothiazide (Diu) 25 mg 0.0030 1.57 1.25 1.88
Atenolol (Bet) 50 mg 0.0084 4.38 3.51 5.26
Nifedepine (Cab) 20 mg 0.0281 29.33 23.47 35.20
Lovastatin (Sta) 20 mg 0.0520 54.28 43.43 65.14
Folic acid 1 mg 0.0271 14.14 11.32 16.97
Table 3: Treatment effects (relative risks) with 95% confidence intervals (CI) of the alternative drugs.
Drug RR Stroke (95% CI) RR CHD (95% CI) Ref.:
Acetylsalicylic acid (Asa) 0.84 (0.75 – 0.93) 0.68 (0.60 – 0.77) [17]
Diuretic drug (Diu) 0.66 (0.55 – 0.78) 0.72 (0.61 – 0.85) [25]
β-blocker (Bet) 0.71 (0.59 – 0.86) 0.93 (0.80 – 1.09) [25]
Calcium antagonist vs diuretic drug or β-blocker (Cab) 0.87 (0.77 – 0.98) 1.12 (1.00 – 1.26) [25, 26]
Statin (Sta) 0.83 (0.75 – 0.91) 0.39 (0.29 – 0.49) [17]
Hypothetical polypill 0.20 (0.13 – 0.29) 0.12 (0.09 – 0.16) [17]Cost Effectiveness and Resource Allocation 2007, 5:3 http://www.resource-allocation.com/content/5/1/3
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One-way sensitivity analyses are performed for key varia-
bles involving value choices. For the discount rate in
DALY calculations we apply a range from 0% (no dis-
counting) to 6%, with 3% as baseline. The age-weight
modeling factor in the DALY calculation [4] is dichoto-
mously varied from 1 (baseline) to 0 (no age-weighting).
Cost-effectiveness acceptability curves
The results are presented as cost-effectiveness acceptability
curves using standard methods [32,34]. Acceptability
curves illustrate the probability that any particular inter-
vention (i) is cost-effective or has a positive net health
benefit, conditional on the willingness to pay per DALY
(λ). For readers who are accustomed to traditional cost-
effectiveness league tables, it is useful to note that the will-
ingness to pay at 50% probability of being optimal for an
intervention corresponds to the mean incremental cost-
effectiveness ratio (ICER) of that intervention compared
to the null-intervention (the alternative of doing none of
the interventions). The curves also illustrate the degree of
uncertainty in the estimates. Acceptability curves with
steep slopes illustrate relatively certain outcomes, while
curves that are less steep mean that the outcomes are rela-
tively more uncertain.
Acceptability curves are used with increasing frequency in
economic evaluations of health interventions, but have to
our knowledge been applied only once before in a devel-
oping country setting [35]. All modeling and calculations
were done using standard software [31].
Cost-effectiveness frontiers
We also present the findings as cost-effectiveness accepta-
bility frontiers that illustrate the probability of any inter-
vention being optimal compared to all its alternatives.
The optimal intervention is defined as the one with the
highest expected net health benefit [32]. Cost-effective-
ness frontiers also illustrate the crossover when one inter-
vention is substituted by another as the one with the
highest probability of being optimal, and therefore pro-
vide useful information for policy makers.
Results
Costs and effects of the interventions
The hypothetical Polypill yields 6.3 expected life years per
person, which as expected is the highest of the alternatives
since this is the most comprehensive treatment. The inter-
vention yielding fewest life years is the β-blocker (Aten-
olol) given as monotherapy, with 0.6 expected life years
per person. The life years saved per person are presented
non-discounted and non-age weighted in Table 5.
While the Polypill is the treatment yielding most life years
of the alternatives, it is also the most expensive alternative.
The expected lifetime cost of such treatment is USD 1755
per person, while the cheapest alternative is the diuretic
drug (Hydrochlorothiazide), with an expected lifetime
cost of USD 74 per person (Table 5).
Cost-effectiveness
The favorable price of Hydrochlorothiazide (Diu) is the
major reason for this intervention having the lowest aver-
age cost-effectiveness ratio (ACER) of the alternatives.
When given as monotherapy to patients with very high CV
risk this intervention cost 85 USD per DALY averted with
baseline assumptions on discounting and age-weighting.
This ratio is not significantly lower than when Hydrochlo-
rothiazide is combined in duo-therapy with Aspirin or a
β-blocker, in triple-therapy with Aspirin and a β-blocker,
or than Aspirin given as mono-therapy. When Hydrochlo-
rothiazide is combined with Aspirin, the ACER increases
to 111 USD per DALY. The intervention with the least
favorable ACER is the calcium antagonist (Nifedepine)
given to people with low CV risk, with an ACER of USD
1095 per DALY averted. The mean average cost-effective-
ness ratios (ACERs) for the 14 drugs in the scenarios of
very high risk relative to the null-intervention are given in
Table 5.
While ACERs are useful background information, rank
ordering of interventions must be done on the basis of
incremental cost-effectiveness ratios (ICERs) after
removal of dominated interventions [33]. From Table 5 it
can be seen that in the very high risk scenario the ICERs
increase from 85 USD per DALY for Hydrochlorothiazide,
to 143, 317, 999 and 1476 USD per DALY when Hydro-
chlorothiazide is combined with Aspirin, Aspirin and a β-
blocker (Atenolol), Aspirin a β-blocker and a statin (Lov-
astatin), and the Polypill, respectively. All the other inter-
ventions are dominated either by strong or extended
dominance.
Table 5 also includes the ICERs for the scenarios of high,
medium and low CV risk, which are higher because the
absolute CV risk and thus the absolute risk reduction is
smaller for these groups.
Uncertainty and value choices
The uncertainty surrounding the above mean ICERs is
captured by the cost-effectiveness acceptability curves in
Figure 2. Some interventions have steep acceptability
curves, illustrating a relatively high level of certainty. The
95% confidence interval (CI) for the ICER of Hydrochlo-
rothiazide given to people with very high CV risk, for
example, is 61 – 133 USD per DALY. Hydrochlorothiazide
in combination with Aspirin have a CI of 108–197 USD
per DALY relative to Hydrochlorothiazide as mono-
therapy.Cost Effectiveness and Resource Allocation 2007, 5:3 http://www.resource-allocation.com/content/5/1/3
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Interventions including Atenolol or Nifedepine, on the
other hand, have acceptability curves that are fare less
steep, illustrating higher levels of model uncertainty. The
ICER of Atenolol in combination with Aspirin and Hydro-
chlorothiazide relative to the previous intervention, for
example, has a CI of 169–3900 USD per DALY. The mean
ICERs with CIs for the non-dominated interventions are
given in Table 5. Figure 2 illustrate the acceptability curves
for people with very high risk. For lower levels of CV risk,
the acceptability curves for all interventions shift right-
wards, while their shapes are roughly the same.
Discounting of future health benefits and age-weighting
are controversial elements of the DALY methodology.
One-way sensitivity analysis for example for Hydrochlo-
rothiazide reveals that when the discount rate on health
effects is set to 0% (no discounting) the ICERs improve
from 85 at baseline (3%) to 70 USD per DALY. When the
discount rate is increased from 3% to 5%, the ICER
increase to 101 USD per DALY and become less attractive
in terms of cost-effectiveness.
Similarly, when the DALYs are calculated without age-
weights [4] the ICERs improve, in the case of Hydrochlo-
rothiazide from 85 to 67 USD per DALY. This happens
because the age weights give less weight to the life years
earned by the elderly, who are the primary targets of pre-
ventive cardiology. Neither age-weighting nor discounting
affect the relative ranking of the interventions in this study
since all interventions target the same age-groups within
similar time spans. But it is clear that the use of age-
weighted and discounted DALYs disfavors preventive car-
diology compared to e.g. interventions targeting child-
hood diseases.
Which interventions are the best choices?
None of the alternative drugs appear to be cost-effective if
the societal willingness to pay for health is lower than 85
USD per DALY. If the willingness to pay is in the range
85–143 USD per DALY, Hydrochlorothiazide as mono-
therapy turn out as the optimal choice for people with
very high risk (>3% annual risk) of cardiovascular disease.
For the range 143 – 317 USD per DALY duo-therapy with
Acetylsalicylic acid and Hydrochlorothiazide is the opti-
mal choice to very high risk people, while a triple therapy
with Acetylsalicylic acid, Hydrochlorothiazide and Aten-
olol turns out to be optimal in the range 317 – 999 USD
per DALY. Finally, when the societal willingness to pay for
health is in the ranges 999–1476 or higher than 1476
USD per DALY, the optimal strategies are to treat patients
with very high risk with a combination of Acetylsalicylic
acid, Hydrochlorothiazide, Atenolol and Lovastatin and
the hypothetical Polypill, respectively. All the other treat-
ment strategies are dominated by the above mentioned.
The above cut-off points are illustrated in the cost-effec-
tiveness acceptability frontier in Figure 3, along with the
probabilities that either policy will maximize the averted
DALYs for different levels of willingness to pay for health.
The main trend when we change the focus from patients
with very high CV risk to lower risk groups is that the cut-
off points between optimal strategies are increased as the
level of risk is reduced (Figure 3). The null intervention,
for example, is probably optimal until the societal willing-
ness to pay for health exceeds 135 USD per DALY in the
Table 5: Mean life time health outcomes, costs and average and incremental cost-effectiveness ratios (CERs) for the drug 
combinations in a scenario with very high CV risk. Incremental CERs are in addition reported for the high, medium and low CV risk 
scenarios. 95% confidence intervals are reported in brackets for the ICERs.
Very high CV risk Incremental CERs (USD/DALY)
Intervention Life years saved
 (nominal)
Costs DALYs ACER
 (USD/DALY)
ICER 
(USD/DALY)
High risk Medium risk Low risk
Asa 1.6 138 0.8 163 (Dominated)
DiuVhigh 1.6 74 0.9 85 85 (61 – 133) 135 (95 – 212) 149 (105 – 230) 232 (163 – 266)
Bet 0.6 107 0.3 329 (Dominated)
Cab 0.7 444 0.4 1095 (Dominated)
Sta 2.7 882 1.6 540 (Dominated)
AsaDiu 3.1 175 1.6 111 143 (108 – 197) 222 (146 – 314) 242 (182 – 337) 377 (280 – 530)
AsaBet 2.2 208 1.1 182 (Dominated)
DiuBet 2.2 141 1.1 124 (Dominated)
AsaDiuBet 3.6 250 1.8 138 317 (169 – 3900) 532 (265 – *) 601 (305 – *) 1009 (465 – *)
AsaDiuSta 4.9 1123 2.6 431 (Dominated)
DiuBetSta 4.6 1086 2.5 433 (Dominated)
AsaBetSta 4.4 1143 2.4 481 (Dominated)
AsaDiuBetSta 5.4 1229 2.8 440 999 (752 – 1376) 1588 (1175–2190) 1739 (1270–2420) 2749 (2010–3850)
Poly 6.3 1755 3.2 557 1476 (545–8000) 2466 (856–16800) 2735 (932–19500) 4589 (1450–51000)
* > 100 000Cost Effectiveness and Resource Allocation 2007, 5:3 http://www.resource-allocation.com/content/5/1/3
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high risk group, while the cut-offs are 149 and 232 in the
medium and low risk scenarios, respectively.
Figure 4 shows that if decision makers in countries such as
Tanzanian have a willingness to pay for health of for
example 50 USD per DALY, none of the treatment alterna-
tives to any of the risk groups should be publicly financed
from a health maximization point of view. If the willing-
ness to pay is somewhat higher, for example 100 USD per
DALY, the optimal treatment mix is to provide Hydro-
chlorothiazide (Diu) to people with very high CV risk, but
no treatment to other risk groups. For a willingness to pay
of say 200 USD per DALY, the optimal policy mix would
be to provide duotherapy with Acetylsalicylic acid and
Hydrochlorothiazide (AsaDiu) to people with very high
risk, monotherapy with Hydrochlorothiazide (Diu) to
patients with medium and high risk, and no drugs to peo-
ple in the low risk group.
Discussion
Our study suggests that the use of Hydrochlorothiazide to
people with high to very high cardiovascular risk is likely
to be the most favorable choice of intervention when the
willingness to pay is higher than some 88 USD per DALY.
Hydrochlorothiazide and several of the alternative drug
combinations costs less than Gross Domestic Product
(USD 300) per capita per DALY averted, and may there-
fore be classified as very cost-effective according to the
Commission on Macroeconomics and Health [36].
Our findings render preventive cardiology somewhat less
attractive in terms of cost-effectiveness compared to the
findings of Murray and colleagues. They report CERs for
an absolute risk approach with statin, diuretic, β-blocker
and aspirin, which is comparable to the AsaDiuBetSta
intervention in our study, in the range 230 – 1010 inter-
national dollars per DALY depending on absolute risk
level. When these findings are converted to USD using a
purchasing power parity of 357 [37] and exchange rate for
year 2000 of 800 TSh/USD, respectively, the ACERs for
these alternatives become 103 – 454 USD per DALY. In
comparison, our study finds a range for the ACERs of 440
– 1148 for these interventions (Table 5). Different analyt-
ical models may explain some of this disparity, but also
the fact that we apply a Tanzanian life table with a life
expectancy at birth of only 46 years is likely to explain
why our model seems to produce fewer DALYs than Mur-
ray and colleagues' study. The differences are not suffi-
ciently large to change the conclusion in both papers that
preventive cardiology is cost-effective based on standard
definitions.
A country like Tanzania has a public health expenditure of
only 6 USD per capita per year [38], which is typical for
Cost-effectiveness acceptability curves for the alternative interventions in the scenario with very high CV risk Figure 2
Cost-effectiveness acceptability curves for the alternative interventions in the scenario with very high CV risk.
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many countries in sub-Saharan Africa. The above conclu-
sion that some of the interventions are cost-effective
should therefore be done with caution and does not auto-
matically imply than any of the interventions should be
recommended for implementation. First, our findings
should be interpreted within the framework of a larger
decision problem and compared with alternative health
interventions with low coverage. Obviously, it is necessary
to consider potential biases caused by differences in per-
spectives and methodology when making such compari-
sons. It has been demonstrated that prevention of mother
to child transmission of HIV is more cost-effective than
any of the treatment alternatives in our analysis [39,40].
Other examples of interventions with low coverage and
ICER appearing to be more favorable in terms of health
maximization than preventive cardiology are improved
case management of acute childhood diarrhea [41], insec-
ticide treated bednets or intermittent presumptive treat-
ment in pregnant women to prevent malaria [42].
Second, our index patients should be interpreted as exam-
ples of very high, high, medium and low cardiovascular
risk, respectively, and whether or not the Framingham
population resembles a Tanzanian population is therefore
not necessarily a critical assumption. There are few studies
from the region on cardiovascular risk, and there is no evi-
dence on outcomes from intervention studies in sub-
Saharan Africa. The possibility that our effect-estimates
are biased therefore cannot be ruled out. It has been sug-
gested that stroke is relatively more important than CHD
in African compared to western Caucasian populations,
particularly because blacks in Africa generally have lower
serum cholesterol levels and higher HDL-levels [11,43],
while other evidence suggest that the contributions of
stroke and CHD to burden of disease in Tanzania are
quite similar [44]. If stroke indeed is the most important
in Tanzania, the cost-effectiveness of drug combinations
including Acetylsalicylic acid and statin, that have their
primary effect on CHD, may have been too favorably esti-
mated in our analysis, while there might be a bias against
interventions controlling blood pressure, that are rela-
tively more effective in prevention of stroke. Moreover,
side-effects of monotherapy with Acetylsalicylic acid has
been suggested to be more problematic in this setting, and
treatment with Acetylsalicylic presuppose adequate blood
pressure control [45].
Third, the efficacy estimates include hard end points
(mortality), and adverse treatment effects with fatal out-
comes are therefore included in our analysis. However,
non-fatal adverse treatment effects, like non-fatal bleeding
caused by acetylsalicylic acid, are not modeled. The excess
absolute risk for major non-fatal bleeds, however, is only
Cost-effectiveness acceptability frontiers in the scenario with very high CV risk Figure 3
Cost-effectiveness acceptability frontiers in the scenario with very high CV risk.
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0.4 [17], which in our models is unlikely to significantly
affect the findings.
We have not calculated the budget impact of a widespread
adoption of the interventions in this paper. The incremen-
tal drug costs per year of treatment are reported in Table 4,
and the life time costs per patient are reported in Table 5,
but since the prevalence of different risk levels is not
known in Tanzania, the costs of scaling up the programs
are difficult to calculate accurately. The budget impact is,
however, likely to be large because a large fraction of the
population probably would be eligible for treatment [7,
46].
Finally, we have considered preventive cardiology from an
efficiency point of view, where the objective is to maxi-
mize societal health given the available resources. We
believe that additional principles for allocation of scarce
resources, like concern for the like concern for the distri-
bution of DALYs, also need to be considered in a priority
setting process. Although we have not made a formal anal-
ysis of this, it is not likely to give high weight to preventive
The optimal strategies (yielding max net health benefits) under different risk scenarios for different levels of societal willingness  to pay for health Figure 4
The optimal strategies (yielding max net health benefits) under different risk scenarios for different levels of societal willingness 
to pay for health. Scales USD 0–5000 per DALY (above) and USD 0–1000 per DALY (below).
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cardiology since such treatment in essence is about treat-
ing people of relatively high age that are not yet sick.
Conclusion
Many countries in sub-Saharan Africa are facing high and
rising levels of cardiovascular disease, and are currently
considering how to meet this challenge. A range of phar-
macological interventions for preventive cardiology are
very cost-effective in a sub-Saharan African setting like Tan-
zania, with Hydrochlorothiazide to patients with high to
very high cardiovascular risk as one of the most likely can-
didates. Despite the attractiveness of this and other inter-
ventions in terms of cost-effectiveness, it is uncertain
whether they should be implemented in a country like
Tanzania. There are several other interventions with low
coverage rates, e.g. treatment of childhood diarrhoea and
malaria, that are even more cost-effective and that are
competing for the same resources. Only when the societal
willingness to pay or the alternative value of incremental
budgets exceeds 85 USD per DALY, preventive cardiology
is likely to be a good choice of policy in Tanzania.
One of the more sophisticated treatment alternatives, the
Polypill, does at present not seem to be a relevant option
for public funding in a country like Tanzania. But coun-
tries with more well-funded health systems, or private per-
sons at risk who can afford to pay for the drugs
themselves, would probably consider such treatment
good value for money. This study suggests that mono-
therapies with Atenolol or Nifedepine are the weakest
candidates for implementation among those compared.
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